Accessibility Menu
Windtree Therapeutics logo

Windtree Therapeutics(OTC) WINT

Current Price$0.00
Market Cap$404.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1997)-100%
5 Year-100%
1 Year-100%
1 Month-99%
Windtree Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-24
Windtree Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-99.24%USD 0.012026-07-17
1 month-99.38%USD 0.022026-06-24
3 month-99.6%USD 0.032026-04-24
Year to date-99.69%USD 0.032025-12-31
1 year-99.99%USD 1.022025-07-24
3 year-100%USD 1,260.002023-07-25
5 year-100%USD 82,267.732021-07-23
Since inception-100%USD 4,166,666,666.671997-11-26

Windtree Therapeutics Financials at a Glance

Market Cap

$404.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$90.00K

Net Income (TTM)

-$40.00M

EPS (TTM)

-$8.51

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.13 (Average)

Price

$0.00

Volume

10,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $1.02

Estimated Earnings Date

Aug 19, 2026

WINT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Windtree Therapeutics

Windtree develops medicines for heart and lung emergencies. Its main drugs aim to help patients with heart failure or breathing problems. These treatments target hospitals and critical care settings.

What’s in the Medicine Cabinet?

  • Istaroxime: Drug in clinical trials for sudden heart failure and early heart shock. 0% of revenue.
  • AEROSURF (KL4 surfactant): Inhaled treatment for breathing distress in premature babies. 0% of revenue.
  • Lyophilized KL4 surfactant: Powdered lung therapy for COVID-19-related injury. 0% of revenue.
  • Rostafuroxin: Drug in trials for high blood pressure linked to genetics. 0% of revenue.
  • aPKCi inhibitor: Early-stage drug for rare cancers and tumors. 0% of revenue.

Plot Twists and Power-Ups

  • Acquired aPKCi inhibitor platform from Varian Biopharmaceuticals in April 2024.
  • Formed research partnerships with Universita degli Studi di Milano-Bicocca and Battelle Memorial Institute.
  • Launched new strategy in January 2025 to buy small companies and approved drugs.
  • Signed $60 million deal in July 2025 to hold Binance Coin (BNB) as a treasury asset.
  • Entered regional partnership with Lee's Pharmaceutical (HK) Ltd. for China market access.

Why Windtree Is a Bit Different

Windtree uses a dual-action drug approach for heart failure, combining two mechanisms in one medicine. The company is shifting from pure research to acquiring revenue-generating assets. Its use of cryptocurrency as a treasury asset is unusual in biotech.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • Net loss was $10.6 million for the three months ended June 30, 2025, improving 11.5% from the same period in 2024.
  • Cash and equivalents were $0.3 million as of June 30, 2025.
  • Current liabilities reached $15.7 million as of June 30, 2025.
  • Accumulated deficit totaled $861.3 million as of June 30, 2025.

Bottom Line

Windtree is evolving from a research-focused biotech to a company seeking revenue through acquisitions and new strategies. Its financial position remains challenging, with ongoing losses and liquidity risks.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Jed Andrew Latkin, MBA

Website

www.windtreetx.com

Headquarters

Warrington, PA 18976-3622, US

WINT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-5612.86%

Return on Capital

-211.70%

Return on Assets

-267.60%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

-0.21%

Stock Overview

Market Cap

$404.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

33.71M

Volume

10.00K

Avg. Volume

96.71K

Financials (TTM)

Gross Profit

-$349.00K

Operating Income

-$33.50M

EBITDA

-$42.60M

Operating Cash Flow

-$15.12M

Capital Expenditure

$0.00

Free Cash Flow

-$15.12M

Cash & ST Invst.

$204.00K

Total Debt

$12.93M

Windtree Therapeutics Performance Analysis

Windtree Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
Windtree Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-31-100.0%
Q22025-06-30N/A
Q32025-09-30N/A
Windtree Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -122,924.70N/A
20222022-12-31USD -56,011.50-54.4%
20232023-12-31USD -4,711.54-91.6%
20242024-12-31USD -104.35-97.8%
Windtree Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31100.1%
Q12025-03-31-1814.8%
Q22025-06-3033.9%
Q32025-09-3064.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$360.00K

-183.5%

Gross Margin

0.00%

N/A

Market Cap

$404.50KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$28.89K

N/A

Employees

14

N/A

Net Income

-$28.09M

-921.6%

EBITDA

-$30.83M

-996.7%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$204.00K

-91.1%

Total Debt

$12.93M

+542.2%

Accounts Receivable

$5.80M

N/A

Inventory

$0.00

N/A

Long Term Debt

$240.00K

-69.4%

Short Term Debt

$12.69M

+932.4%

Return on Assets

-2.68%

N/A

Return on Invested Capital

4.72%

N/A

Free Cash Flow

-$6.37M

+1.1%

Operating Cash Flow

-$6.37M

+1.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
XRTXXORTX Therapeutics Inc.
$2.03-3.57%
VRAXVirax Biolabs Group Limited
$3.19+0.00%
DRMADermata Therapeutics, Inc.
$1.32+4.71%
ATXIAvenue Therapeutics, Inc.
$0.28+6.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
AALAmerican Airlines Group
$14.48+0.07%

Questions About WINT

What is the current price of Windtree Therapeutics?

Windtree Therapeutics is trading at $0.00 per share.

What is the 52-week range for Windtree Therapeutics?

Over the past 52 weeks, Windtree Therapeutics has traded between $0.00 and $1.02.

How much debt does Windtree Therapeutics have?

As of the most recent reporting period, Windtree Therapeutics reported total debt of $12.93M.

How much cash does Windtree Therapeutics have on hand?

Windtree Therapeutics reported $204.00K in cash and cash equivalents in its most recent financial results.

What is Windtree Therapeutics’s dividend yield?

Windtree Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services